PE-22-28
PE 22-28; mini-spadin; shortened spadin analog (residues 22-28 of the sortilin propeptide); CAS 1801959-12-5
This peptide has not been evaluated by the FDA. It is sold as a research chemical and has no regulatory status for human use.
A synthetic peptide that blocks a specific brain channel involved in mood regulation, producing rapid antidepressant-like effects and stimulating new brain cell growth in animal studies. No human clinical trials have been conducted, so its safety and effectiveness in people are unknown.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Safety Summary
All side effect data for PE-22-28 comes from either preclinical animal studies or uncontrolled anecdotal community reports. No formal Phase I-III clinical trial safety data exist, and no precise incidence rates or graded severity distributions have been documented in the public literature. Preclinical mouse studies (PMC5601071) reported no toxicity or dose-limiting adverse effects. Community anecdotal reports indicate a dose-dependent side effect profile: lower doses (100-400 mcg) are generally well-tolerated with cognitive/mood benefits, while higher doses (500+ mcg) increase the risk of sedation/lethargy. Tolerance development over weeks of continuous use is commonly reported, with many users recommending periodic washouts (2-8 weeks off) to restore effect. No serious adverse events have been reported in FAERS or EudraVigilance public databases. No GLP repeated-dose toxicology, carcinogenicity, reproductive/developmental, or immunogenicity studies have been conducted. Long-term safety in humans is entirely unknown. No clinical withdrawal syndrome has been documented, though this absence of evidence does not constitute evidence of absence given the lack of controlled study.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-3]